Remimazolam
- TRADE NAME: Byfavo (Acacia Pharma)
- INDICATIONS: Induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less (intravenous administration).
- SYNONYM: Remimazolam besylate
- CLASS: Benzodiazepine
- HALF-LIFE: 37–53 minutes (terminal elimination half-life from plasma)
FDA APPROVAL DATE: 07/02/2020
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
Benzodiazepines cross the placenta and may produce respiratory depression and sedation in neonates.
Remimazolam should not be used in patients less than 18 years of age. Remimazolam may cause confusion and over-sedation in the elderly; elderly patients generally should be observed closely.
A case of intravenous line occlusion has been reported when using Acetated Ringer's solution and remimazolam (https://doi.org/10.1016/j.jclinane.2021.110190).
REMIMAZOLAM HAS BEEN ASSOCIATED WITH HYPOXIA, BRADYCARDIA, AND HYPOTENSION. CONCOMITANT USE OF BENZODIAZEPINES WITH OPIOID ANALGESICS MAY RESULT IN PROFOUND SEDATION, RESPIRATORY DEPRESSION, COMA, AND DEATH. THE SEDATIVE EFFECT OF INTRAVENOUS REMIMAZOLAM CAN BE ACCENTUATED BY CONCOMITANTLY ADMINISTERED CNS DEPRESSANT MEDICATIONS, INCLUDING OTHER BENZODIAZEPINES AND PROPOFOL.
See full prescribing information for complete boxed warning
Please login to see the rest of this drug profile
Page last updated 01/31/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric